Assetmark Inc. Acquires 12,984 Shares of Agilent Technologies, Inc. $A

Key Points

• Assetmark Inc. increased its stake in Agilent by 5.9% in Q4, buying 12,984 shares to hold 234,275 shares valued at about $31.9 million (0.08% of the company).
• Massachusetts Financial Services made a much larger move, adding 1,713,216 shares in Q4 to hold 14,147,601 shares worth roughly $1.93 billion, signaling significant institutional accumulation.
• Agilent slightly missed Q4 estimates (EPS $1.36 vs. $1.37; revenue $1.80B vs. $1.81B) though revenue rose 7% YoY, and the company gave FY2026 EPS guidance of 5.90–6.04 (above sell-side consensus of 5.58); it also declared a $0.255 quarterly dividend (0.8% yield).

Assetmark Inc. increased its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 234,275 shares of the medical research company's stock after buying an additional 12,984 shares during the period. Assetmark Inc. owned 0.08% of Agilent Technologies worth $31,878,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Kelsey Financial LLC purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $995,000. Choreo LLC increased its holdings in shares of Agilent Technologies by 6.4% in the 4th quarter. Choreo LLC now owns 8,946 shares of the medical research company's stock worth $1,231,000 after buying an additional 539 shares during the last quarter. Dara Capital US Inc. bought a new position in shares of Agilent Technologies during the 4th quarter valued at $106,000. Ritholtz Wealth Management grew its holdings in shares of Agilent Technologies by 8.9% during the 4th quarter. Ritholtz Wealth Management now owns 1,868 shares of the medical research company's stock valued at $254,000 after purchasing an additional 153 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Agilent Technologies by 13.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company's stock valued at $1,925,064,000 after purchasing an additional 1,713,216 shares during the last quarter.

Agilent Technologies Trading Up 2.5%

Shares of NYSE A opened at $120.40 on Wednesday. Agilent Technologies, Inc. has a 1 year low of $99.12 and a 1 year high of $160.27. The stock has a market cap of $34.03 billion, a P/E ratio of 26.58, a price-to-earnings-growth ratio of 2.47 and a beta of 1.30. The firm has a 50-day moving average of $118.76 and a 200 day moving average of $134.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.37 by ($0.01). The business had revenue of $1.80 billion for the quarter, compared to analysts' expectations of $1.81 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The company's revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be issued a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.8%. Agilent Technologies's payout ratio is 22.52%.

Wall Street Analysts Forecast Growth

A has been the topic of several recent research reports. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Agilent Technologies in a report on Monday, December 29th. UBS Group dropped their price target on shares of Agilent Technologies from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Barclays dropped their price target on shares of Agilent Technologies from $150.00 to $140.00 and set an "overweight" rating for the company in a research report on Tuesday. Evercore raised shares of Agilent Technologies from an "in-line" rating to an "outperform" rating and increased their price target for the company from $155.00 to $160.00 in a research report on Monday, January 5th. Finally, Morgan Stanley dropped their price target on shares of Agilent Technologies from $180.00 to $160.00 and set an "overweight" rating for the company in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $160.53.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.